These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29617367)

  • 21. Systematically identify key genes in inflammatory and non-inflammatory breast cancer.
    Chai F; Liang Y; Zhang F; Wang M; Zhong L; Jiang J
    Gene; 2016 Jan; 575(2 Pt 3):600-14. PubMed ID: 26403314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2.
    Mohamed HT; El-Ghonaimy EA; El-Shinawi M; Hosney M; Götte M; Woodward WA; El-Mamlouk T; Mohamed MM
    Toxicol Appl Pharmacol; 2020 Aug; 401():115092. PubMed ID: 32512068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reproductive Risk Factors of Inflammatory Breast Cancer according to Luminal, HER2-Overexpressing, and Triple-Negative Subtypes: A Case Comparison Study.
    Mejri N; El Benna H; Rachdi H; Labidi S; Benna M; Daoud N; Hamdi Y; Abdelhak S; Boussen H
    Oncol Res Treat; 2020; 43(5):204-210. PubMed ID: 32203954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated network analysis and machine learning approach for the identification of key genes of triple-negative breast cancer.
    Naorem LD; Muthaiyan M; Venkatesan A
    J Cell Biochem; 2019 Apr; 120(4):6154-6167. PubMed ID: 30302816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.
    Bekhouche I; Finetti P; Adelaïde J; Ferrari A; Tarpin C; Charafe-Jauffret E; Charpin C; Houvenaeghel G; Jacquemier J; Bidaut G; Birnbaum D; Viens P; Chaffanet M; Bertucci F
    PLoS One; 2011 Feb; 6(2):e16950. PubMed ID: 21339811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression.
    Clarkson RW; Wayland MT; Lee J; Freeman T; Watson CJ
    Breast Cancer Res; 2004; 6(2):R92-109. PubMed ID: 14979921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.
    Van Laere SJ; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; van Dam P; Woodward WA; Viens P; Cristofanilli M; Birnbaum D; Dirix L; Reuben JM; Bertucci F
    Clin Cancer Res; 2013 Sep; 19(17):4685-96. PubMed ID: 23396049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness.
    Lerebours F; Cizeron-Clairac G; Susini A; Vacher S; Mouret-Fourme E; Belichard C; Brain E; Alberini JL; Spyratos F; Lidereau R; Bieche I
    Int J Cancer; 2013 Oct; 133(7):1614-23. PubMed ID: 23526361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory breast cancer (IBC): clues for targeted therapies.
    Fernandez SV; Robertson FM; Pei J; Aburto-Chumpitaz L; Mu Z; Chu K; Alpaugh RK; Huang Y; Cao Y; Ye Z; Cai KQ; Boley KM; Klein-Szanto AJ; Devarajan K; Addya S; Cristofanilli M
    Breast Cancer Res Treat; 2013 Jul; 140(1):23-33. PubMed ID: 23784380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer.
    Provance OK; Lewis-Wambi J
    Breast Cancer Res; 2019 May; 21(1):59. PubMed ID: 31060575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Robust inflammatory breast cancer gene signature using nonparametric random forest analysis.
    Zare A; Postovit LM; Githaka JM
    Breast Cancer Res; 2021 Sep; 23(1):92. PubMed ID: 34579745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteome profiling of triple negative breast cancer cells overexpressing NOD1 and NOD2 receptors unveils molecular signatures of malignant cell proliferation.
    Velloso FJ; Campos AR; Sogayar MC; Correa RG
    BMC Genomics; 2019 Feb; 20(1):152. PubMed ID: 30791886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MARCKS protein overexpression in inflammatory breast cancer.
    Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
    Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity.
    Rypens C; Marsan M; Van Berckelaer C; Billiet C; Melis K; Lopez SP; van Dam P; Devi GR; Finetti P; Ueno NT; Bertucci F; Dirix P; Neven P; Vermeulen P; Dirix L; Van Laere SJ
    Breast Cancer Res Treat; 2020 Apr; 180(2):385-395. PubMed ID: 32043194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
    Hamm CA; Moran D; Rao K; Trusk PB; Pry K; Sausen M; Jones S; Velculescu VE; Cristofanilli M; Bacus S
    Mol Cancer Ther; 2016 Jul; 15(7):1746-56. PubMed ID: 27196778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.
    Eckhardt BL; Gagliardi M; Iles L; Evans K; Ivan C; Liu X; Liu CG; Souza G; Rao A; Meric-Bernstam F; Ueno NT; Bartholomeusz GA
    PLoS One; 2018; 13(5):e0195932. PubMed ID: 29768500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel key genes in triple-negative breast cancer identified by weighted gene co-expression network analysis.
    Chen J; Qian X; He Y; Han X; Pan Y
    J Cell Biochem; 2019 Oct; 120(10):16900-16912. PubMed ID: 31081967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miRNome of inflammatory breast cancer.
    Maltseva DV; Galatenko VV; Samatov TR; Zhikrivetskaya SO; Khaustova NA; Nechaev IN; Shkurnikov MU; Lebedev AE; Mityakina IA; Kaprin AD; Schumacher U; Tonevitsky AG
    BMC Res Notes; 2014 Dec; 7():871. PubMed ID: 25471792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.